Gilead faces rating downgrade due to growth constraints
Gilead Sciences has faced a rating downgrade after a significant 50% stock rally. Analysts cite growth constraints as the main reason for this change. Previously, Gilead's strong performance was largely attributed to its HIV treatment, Biktarvy. However, concerns about future growth have now impacted its rating. This downgrade marks a shift in investor sentiment following a period of strong stock performance. The company's growth potential is now under closer scrutiny.